key: cord-0905207-7r77gj80
authors: Kufel, Wesley D.
title: Antibody-based strategies in HIV therapy
date: 2020-10-09
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2020.106186
sha: a1cff681aa82fcbb0f3b1154d6659750f2486378
doc_id: 905207
cord_uid: 7r77gj80

Antibody-based strategies have been introduced for a number of disease states, but represent a novel approach in HIV management. Ibalizumab and leronlimab are monoclonal antibodies with unique mechanisms as a CD4-directed post-attachment inhibitor and C-C chemokine receptor type 5-directed inhibitor, respectively. These antibody-based strategies are generally well-tolerated, have a favorable pharmacokinetic profile allowing for less frequent dosing, and have a high barrier to resistance. Ibalizumab is currently approved by the United States Food and Drug Administration (US FDA) for management of multidrug-resistant (MDR) HIV infection in patients who are failing their current regimens. Clinical data demonstrated impressive antiretroviral activity with ibalizumab among a complex HIV population in combination an optimized background regimen, where limited therapeutic options exist. Leronlimab has not been granted approval by the US FDA, but has been designated fast-track status. Leronlimab is being studied as a maintenance monotherapy agent in virologically suppressed patients as well as for treatment of MDR HIV infection in patients who are failing their current regimens. Currently available data in both of these potential areas appears promising for leronlimab. The mechanism of action, pharmacokinetic profile, efficacy, and safety of these novel antibody-based strategies present an advance in the management of HIV. Future studies and postmarketing experience will further determine longer-term clinical efficacy, safety, and resistance data for ibalizumab and leronlimab.

Antiretroviral therapy (ART) has considerably improved the prognosis of patients infected with Human Immunodeficiency Virus (HIV). However, approximately 95% adherence to ART is required to maintain viral suppression, decrease opportunistic infections, and minimize antiretroviral resistance.

1 While ART has generally become simpler, adherence can still be challenging due to complex dosing regimens, frequent administrations, drug interactions, and dietary considerations. 2 As such, there is a need for antiretrovirals with less frequent dosing and higher barriers to resistance. 3 Furthermore, several patients with complex ART regimens are still unable to meet viral suppression due to multidrug-resistant (MDR) HIV, and are more vulnerable to treatment failure, 4 worse clinical outcomes, and increased mortality. [5] [6] [7] One area of interest for these niches in HIV therapeutics is the development of antibody-based strategies. 8 Several monoclonal antibodies already exist for treatment of multiple diseases including autoimmune diseases, cancers, and infectious diseases. Antibody-based strategies for HIV offer a unique mechanism of action, decreased potential for development of acquired resistance, and improved potential safety profile, especially for MDR HIV infection where limited effective and well-tolerated antiretrovirals exist. 9 This review highlights various antibody-based strategies and their role in HIV management with a focus on ibalizumab and leronlimab. Literature searches were performed using PubMed, EMBASE, and Google Scholar. Search terms included antibody, monoclonal antibody, HIV, multidrug resistant HIV, ibalizumab, leronlimab, and PRO 140 to identify peerreviewed publications as of September 20, 2020. Abstracts, posters, and press releases were utilized if data were not yet available as published articles. A brief comparative summary of ibalizumab and leronlimab is displayed in Table 1 .

Ibalizumab is currently the only monoclonal antibody approved by the United States Food and Drug Administration (US FDA) for HIV, specifically in combination with other antiretrovirals for heavily treatment-experienced adults who are failing their current regimen. 10 Ibalizumab is a recombinant humanized immunoglobulin G (IgG) 4 monoclonal antibody that exhibits a unique mechanism of action as a CD4 post-attachment inhibitor. 11, 12 Traditionally in HIV infection, the HIV envelope glycoprotein 120 (gp120) binds to CD4 cell extracellular domain 1, which leads to a conformational shift in V1 and V2 loops that subsequently exposes the V3 loop and causes a shift from a closed to open state. 13 However, ibalizumab binds to amino acid positions within domain 1 and 2 of the CD4 cell, which induces steric hinderance and prevents the aforementioned conformational changes between gp120 and the CD4 cell to ultimately prevent viral fusion. 11 Ibalizumab's activity is independent of C-X-C chemokine receptor type 4 (CXCR4)-and C-C chemokine receptor type 5 (CCR5)-tropic strains because of its unique steric hinderance mechanism.

Ibalizumab is administered as a 2000 mg intravenous loading dose followed by a maintenance dose of 800 mg intravenously every 14 days. 10, 12 Following the 2000 mg loading dose, the maximum concentration was 567 mcg/ml. Following administration of the 800 mg maintenance dose every 14 days, the mean concentration was ≥30 mcg/ml and demonstrated a time above the EC 85 (i.e. concentration required for ≥85% receptor occupancy) of 100% throughout the dosing interval.

Ibalizumab appears to demonstrate a linear, dose-dependent exposure. 14 The estimated half-life of ibalizumab following maintenance dosing is approximately 72 to 84 hours, 14,15 which is considerably less than the 2-3 week half-life of IgG. 14 This difference in half-life is due to different clearance mechanisms such as internalization or shedding for the ibalizumab-CD4 receptor complex. 16 In the phase III study, 97% and 81% of subjects exhibited at least 85% CD4 cell receptor occupancy following the approved dosing regimen at day 21 and week 25, respectively. 12 Regardless of baseline resistance profiles, ibalizumab exhibited similar maximal percentage of inhibition (MPI) compared to other antiretrovirals including nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, enfuvirtide, or maraviroc.

While less frequent dosing may be advantageous, missed doses may compromise the effectiveness of ibalizumab. If a maintenance dose is missed by ≥3 days, a loading dose should be readministered immediately, followed by maintenance dosing every 14 days thereafter. No specific studies have been performed to assess the impact of hepatic or renal dysfunction on ibalizumab's pharmacokinetics, yet these are not expected to alter such parameters. 10 Furthermore, no specific drug interaction studies have been performed, but interactions are not anticipated given the mechanism of action of ibalizumab.

Ibalizumab was studied in two phase I, 14,15 two phase II (TNX-355.03 and TMB-202), 18, 19 and two phase III clinical trials (TMB-301 and TMB-311). 12 Phase II and phase III clinical trial data are summarized in Table 2 .

TNX-355.03 was a phase IIa, randomized double blind, placebo-controlled study to investigate the effect of two ibalizumab dosing strategies on HIV RNA concentrations at week 24 and 48 (Table 2) . 18 In addition to an optimized background regimen (OBR) guided by antiretroviral resistance testing, subjects were randomized to receive: (1) 15 mg/kg every 2 weeks (n=28), (2) 10 mg/kg every week for 9 doses followed by every 2 weeks (n=27), or (3) placebo (n=27). Both ibalizumab dosing regimens achieved statistically significant reductions in HIV RNA at 24 and 48 weeks. The mean CD4 count increased from 223 cells/mm 3 to 274 cells/mm 3 (p=0.016) and from 299 cells/mm 3 to 347 cells/mm 3 (p=0.031) at 48 weeks for the 15 mg/kg IV every 14 days regimen and for the loading dose followed by maintenance dosing regimen, respectively.

TMB-202 was a phase IIb, randomized, double-blind, dose-response study to investigate two ibalizumab dosing strategies plus OBR on undetectable viral load achievement at week 24 (Table 2) . 19 In addition to OBR, subjects were randomized to receive ibalizumab 800 mg IV every 14 days (n=59) or 2000 mg IV every 4 weeks (n=54). The mean reductions in HIV RNA from baseline, percentage of subjects achieving a 1.0 log 10 reduction in HIV RNA, and mean increases in CD4 were similar between both regimens at week 24. Pharmacokinetic investigations led to the dosing regimen used in the phase III study.

TMB-301 was a phase III, single-group, open-label study to evaluate ibalizumab on HIV RNA decline in 40 subjects with MDR HIV-1 infection who were failing their current ART regimen (Table 2) . 12 This study was conducted across three time periods:

control (days 0-6) where subjects continued their prior ART, functional monotherapy (day 7-13) where subjects received ibalizumab 2000 mg and continued their prior ART, and maintenance (day 14 to week 25) where subjects started an OBR and received ibalizumab 800 mg every 14 days starting on day 21. Baseline mean HIV RNA was >100,000 copies/ml, 17 (43%) subjects had a CD4 <50 cells/mm 3 , and documented resistance to all drugs in at least one, two, three, or four ART classes were 85%, 73%, 50%, and 33%, respectively. Five (13%) subjects had documented resistance to all approved antiretrovirals, and 17 (43%) subjects required fostemsavir, an investigational antiretroviral, to create an OBR. While 40 subjects were included in the intention-to-treat analysis, 31 completed the study. TMB-311 was a phase III clinical trial to allow subjects who completed TMB-301 to continue ibalizumab through 48 weeks (Table 2) . 20 All 15 subjects with HIV RNA <50 copies/ml at the end of TMB-301 maintained undetectable viral loads at 48 weeks. A subgroup analysis of TMB 301/311 also demonstrated comparable and durable virologic efficacy regardless of the number of active agents among subjects who received ibalizumab in combination with one or two fully active agents. 21

Resistance to ibalizumab may develop through decreased interactions between HIV gp120 and CD4 cells that minimize steric hinderance and therapeutic effect of ibalizumab.

22,23 Specifically, reduced expression or loss of N-linked glycosylation sites (PNGS) in variable region 5 (V5) of gp120 is considered the primary mechanism. Loss of PNGS was the primary modification associated with reduced ibalizumab susceptibility in TMB-301; however, a reduced MPI from baseline was not predictive of virologic failure or rebound. 20 Resistance has been observed to develop within 1-2 weeks in patients receiving ibalizumab monotherapy. 24 Decreased virologic response and concern for resistance has also been noted with even one missed infusion in subjects who received 2000 mg every 4 weeks, emphasizing the importance of adherence. 19 Currently, there are no commercially available resistance testing methods for patients with suspected resistance to ibalizumab. 9 Cross-resistance between ibalizumab and other antiretrovirals, particularly entry inhibitors such as maraviroc or enfuvirtide, has not been reported. 11 One subject developed anti-ibalizumab antibodies in TMB-202, but titers were low, and drug efficacy was not impacted. 19 No other studies observed development of anti-ibalizumab antibodies.

12,15

While not FDA approved currently, leronlimab (previously known as PRO 140) is a humanized IgG4, kappa monoclonal antibody directed towards CCR5 that has reemerged as a potential novel agent for HIV treatment. 25 

Leronlimab is administered as a subcutaneous injection every week based on its favorable pharmacokinetic profile. 29 The mean half-life of leronlimab after multiple subcutaneous doses was 3.4 and 3.7 days at 162 mg and 342 mg, respectively.

Leronlimab metabolism is mediated through a saturable antigen clearance mechanism, and thus, no dose adjustments are needed in patients with hepatic or renal dysfunction. 25 Furthermore, drug-drug interactions are not anticipated. After a single IV 5 mg/kg dose (350 mg for a 70 kg patient), CCR5 receptor coating was observed for greater than 60 days. 30 More than 85% of receptor occupancy was observed through day 29 at 5 and 10 mg/kg, and 81% was observed at day 43 of 10 mg/kg. 31 Specific leronlimab dosing regimens are still being investigated.

Leronlimab has been studied in nine clinical trials to date including four phase I studies (including unpublished data), 25, 32 three phase II studies, 29-31 and two-phase III extension studies. 33,34 Leronlimab has been granted fast-track status by the US FDA.

Phase IIb and phase III clinical trial data are summarized in Table 2 , yet partial data from these studies continue to emerge through abstracts, conference presentations, press releases, and published manuscripts.

CD01 is a phase IIb, randomized, open label study to investigate leronlimab monotherapy to maintain viral suppression for over 24 months. 30 Leronlimab 350 mg was administered subcutaneously every week for 12 weeks in combination with their current ART. After one week, their combination ART was discontinued, and leronlimab was continued as monotherapy to avoid the possibility of viral rebound. Subjects who experienced viral rebound (HIV RNA >400 copies/mL on 2 consecutive draws ≥3 days apart) restarted their original ART. Forty-three subjects were enrolled, but two subjects were removed because they had mixed tropism prior to leronlimab receipt. 35 Thus, 41 subjects were studied through three cohorts: one (n=11), two (n=28), and three (n=2). More than half of the enrolled subjects maintained virologic suppression at 12 weeks. Sixteen subjects from cohorts two and three entered the CD01 extension study for follow-up over 160 weeks.

Similar to CD01, CD03 is an ongoing phase IIb/III, randomized, open-label study to investigate leronlimab monotherapy at doses of 350 mg, 500 mg, or 700 mg weekly for 48 weeks. 30, 36 In part 1, 156 subjects received 350 mg subcutaneously every week.

In part 2, 147 subjects received 350 or 525 mg in a 1:1 ratio as a randomized controlled, two-arm study. In part 3 (ongoing), 47 subjects are randomized to receive 525 or 700 mg in a 1:1 ratio. More than 90% of subjects who received 700 mg achieved viral suppression without any increased safety risk for up to 12 weeks compared to 71% and 44% with 525 mg and 350 mg, respectively. 36 Central nervous system and genitourinary substudies are also included to evaluate leronlimab concentrations and HIV RNA at these sites.

CD02 was a randomized, double blind, placebo-controlled trial that investigated the efficacy, safety, and tolerability of leronlimab in treatment-experienced HIV subjects. 37, 38 Leronlimab 350 mg or placebo was added to their failing ART for one week followed by the single-arm, open-label treatment period of leronlimab in combination with an OBR for 25 weeks. Leronlimab 350 mg was administered subcutaneously every week. Of 52 subjects enrolled, 47 completed the 25-week period with 40 subjects who requested to continue receiving leronlimab in an extension study. Several of these subjects have maintained viral suppression for more than two years.

The primary mechanism of resistance is emergence of CXCR4 or mixed tropism. However, this observation has been rare. To date, five subjects reported CXCR4 tropism shift, but three had mixed tropism present at baseline among subjects who had tropism data available (n=170). 3, 25, 29, 31 One subject had mixed tropism at day 8, but CCR5 tropism at all other study time points. 25 Additionally, two had temporary emergence of CXCR4 tropism, which later returned to CCR5 tropism at study completion.

Ibalizumab and leronlimab are novel monoclonal antibodies with unique mechanisms of action as a CD4-directed postattachment inhibitor and CCR5-directed inhibitor, respectively. 3, 9 Both agents are generally well-tolerated, have less frequent dosing, lack drug interactions, and have a high barrier to resistance making them intriguing options for niche roles in HIV management. Antibody-based strategies may also have a role in capacities other than MDR HIV management and maintenance monotherapy including pre-exposure prophylaxis, post-exposure prophylaxis, and mother-to-child transmission. Interest has also even spurred in the combined use of ibalizumab and leronlimab particularly for treatment-experienced patients. 35 Ibalizumab is currently the only monoclonal antibody approved for treatment of HIV, specifically in patients with MDR HIV who are failing their current regimen. 9 This patient population is highly complex, and limited options are available as represented in the patient population studied in TMB-301. 12 Fortunately, ibalizumab was well-tolerated from a safety perspective. While ibalizumab is available as an intravenous infusion, administration can occur in multiple settings, and alternative routes of administration such as intramuscular and subcutaneous injections have been explored. 24, 39 As with most monoclonal antibodies, ibalizumab is costly with an estimated wholesale annual cost of approximately $120,000. 40 A cost-effectiveness analysis was performed to compare ibalizumab plus OBR to OBR alone. 41 Based on these results, ibalizumab will substantially increase survival when effective for patients with MDR HIV lacking other treatment options. Interestingly, the addition of ibalizumab to an OBR was found not to be cost-effective even with 100% efficacy; however, the number of patients eligible to receive ibalizumab is generally considered to be low and the overall budget impact is thought to be relatively small. Nonetheless, ibalizumab remains a salvage option in a challenging MDR HIV patient population.

Leronlimab has been studied as maintenance monotherapy in virologically suppressed patients as well as for treatment of MDR HIV in combination with other ART.

3 Unlike ibalizumab, leronlimab is primarily being studied as a subcutaneous injection. As maintenance monotherapy, leronlimab demonstrated promise in maintaining virologic suppression, especially at higher doses without compromising safety. In this capacity, leronlimab offers a potential long acting, monotherapy maintenance regimen. Similar to ibalizumab, leronlimab has also demonstrated notable virologic suppression results in treatment-experienced, MDR HIV patients who have limited options available. Leronlimab has received fast-track designation, but still has yet to be approved by the US FDA.

Although more clinical data remain to be revealed by future studies and postmarketing experience, ibalizumab and leronlimuab represent novel antibody-based strategies for HIV management with roles in multiple potential capacities where treatment options are critically needed.

Funding: This work was carried out as part of my routine practice.

Competing Interests: Wesley D. Kufel has served on the advisory board for Theratechnologies, Inc., and received research grant funding from Merck and Melinta Therapeutics. 

Adherence to antiretroviral therapy and factors affecting low medication adherence among incident HIV-infected individuals during 2009-2016: A nationwide study

</bib> <bib id="bib3" type="Periodical"><number>3.</number> Thompson MA. The return of PRO 140, a CCR5-directed mAb

</bib> <bib id="bib11" type="Periodical"><number>11.</number> Iacob SA, Iacob DG. Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy

Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults

TNX-355 in combination with optimized background regimen (OBR), achieves statistically significant viral load reduction and CD4 cell count increase when compared with OBR alone in phase 2 study at 48 weeks. International AIDS Conference. Toronto, Canada.</bib> <bib id="bib19" type="Proceeding"><number>19

Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5

Bethesda (MD):National Library of Medicine (US).</bib> <bib id="bib34" type="Book"><number>34.</number> CytoDyn, Inc. 2016. A Phase 2b/3, multicenter study to assess the treatment strategy of using PRO 140 SC as long-acting single-agent maintenance therapy for 48 weeks in virologically suppressed subjects with CCR5-tropic HIV-1 infection